Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | -5,4x - -5,9x | -5,6x |
| Selected Fwd EBIT Multiple | -28,0x - -30,9x | -29,5x |
| Fair Value | $3,97 - $4,45 | $4,21 |
| Upside | -5,6% - 5,7% | 0,0% |
| Benchmarks | Ticker | Full Ticker |
| Dyadic International, Inc. | DYAI | NasdaqCM:DYAI |
| Geron Corporation | GERN | NasdaqGS:GERN |
| Trevena, Inc. | TRVN | OTCPK:TRVN |
| Protalix BioTherapeutics, Inc. | PLX | NYSEAM:PLX |
| ADMA Biologics, Inc. | ADMA | NasdaqGM:ADMA |
| TriSalus Life Sciences, Inc. | TLSI | NasdaqGM:TLSI |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| DYAI | GERN | TRVN | PLX | ADMA | TLSI | ||
| NasdaqCM:DYAI | NasdaqGS:GERN | OTCPK:TRVN | NYSEAM:PLX | NasdaqGM:ADMA | NasdaqGM:TLSI | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | |
| Latest Twelve Months | 30.5% | 36.0% | 6.9% | -42.6% | 223.0% | 38.5% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | -420.4% | -23737.0% | -15325.1% | -12.3% | -40.5% | -251.5% | |
| Prior Fiscal Year | -282.6% | -81832.9% | 13486.8% | 16.0% | 9.5% | -271.1% | |
| Latest Fiscal Year | -168.2% | -225.6% | -1129.2% | 7.3% | 32.6% | -122.9% | |
| Latest Twelve Months | -161.9% | -115.5% | -5880.0% | 7.7% | 33.1% | -99.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 9.64x | 4.33x | 44.58x | 1.44x | 9.76x | 5.13x | |
| EV / LTM EBITDA | NA | -3.8x | -0.8x | 14.5x | 28.0x | -5.3x | |
| EV / LTM EBIT | -6.0x | -3.8x | -0.8x | 18.7x | 29.5x | -5.2x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -6.0x | -0.8x | 29.5x | ||||
| Historical EV / LTM EBIT | -11.3x | -4.3x | -4.0x | ||||
| Selected EV / LTM EBIT | -5.4x | -5.6x | -5.9x | ||||
| (x) LTM EBIT | (32) | (32) | (32) | ||||
| (=) Implied Enterprise Value | 170 | 179 | 188 | ||||
| (-) Non-shareholder Claims * | (20) | (20) | (20) | ||||
| (=) Equity Value | 150 | 159 | 168 | ||||
| (/) Shares Outstanding | 37.8 | 37.8 | 37.8 | ||||
| Implied Value Range | 3.97 | 4.20 | 4.44 | ||||
| FX Rate: USD/USD | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 3.97 | 4.20 | 4.44 | 4.21 | |||
| Upside / (Downside) | -5.8% | -0.1% | 5.5% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | DYAI | GERN | TRVN | PLX | ADMA | TLSI | |
| Enterprise Value | 33 | 430 | 24 | 84 | 4,537 | 179 | |
| (+) Cash & Short Term Investments | 7 | 397 | 13 | 35 | 72 | 13 | |
| (+) Investments & Other | 0 | 59 | 0 | 0 | 0 | 0 | |
| (-) Debt | (5) | (122) | (38) | (5) | (82) | (33) | |
| (-) Other Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 35 | 764 | 0 | 113 | 4,526 | 159 | |
| (/) Shares Outstanding | 36.2 | 636.9 | 1.0 | 79.6 | 238.7 | 37.8 | |
| Implied Stock Price | 0.98 | 1.20 | 0.25 | 1.42 | 18.96 | 4.21 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 0.98 | 1.20 | 0.25 | 1.42 | 18.96 | 4.21 | |
| Trading Currency | USD | USD | USD | USD | USD | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |